7 results about "Haematological malignancy" patented technology

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

The present disclosure relates to methods for treating blood transfusion-dependent hematological malignancy patients with oxygen reduced blood.

The invention discloses a triptolide peptide conjugate as well as a pharmaceutical composition and application thereof, and successfully designs and synthesizes the triptolide peptide conjugate which shows remarkable tumor cell proliferation inhibition activity. K-1 shows an excellent inhibition effect on a specific solid tumor cell strain; K-1 has particularly outstanding inhibition activity on a hepatoma cell strain HuH-7, a pancreatic cancer cell strain MIA PaCa-2 and a gastric cancer cell strain HGC-27; the compound shows broad-spectrum and high-efficiency anti-tumor characteristics as shown in the formula K-1, K-2 and K-3, and shows excellent inhibitory activity on a hepatoma cell line HepG2, an acute myelogenous leukemia cell line KG-1, a multiple myeloma cell line RPMI-8226 and a pancreatic cancer cell line MIA PaCa-2. The result not only proves the effectiveness of the K-3 on various solid tumors, but also highlights the strong inhibition effect of the K-3 on malignant tumors of a blood system, and shows the prospect of the K-3 as a broad-spectrum anti-tumor candidate drug. And a powerful guarantee is provided for subsequent deep development of potential antitumor candidate drug molecules and final realization of clinical application transformation.

The application discloses a D-A-D type organic small molecule, nanoparticles containing the same, and a preparation method and application thereof. The D-A-D type organic small molecule and the nanoparticles thereof are particularly suitable for precise photothermal treatment and real-time imaging guidance of hematological malignancies such as leukemia, lymphoma and multiple myeloma. The D-A-D type organic small molecule constructs a D-A-D type conjugated structure, realizes near-infrared absorption red shift to 685 nm through enhancing intramolecular charge transfer (ICT) effect, and promotes non-radiative transition by using high excited state reorganization energy (lambda=1.29eV), with a photothermal conversion efficiency of more than 35%. The small molecule does not contain metal and halogen, has a molecular weight of about 878 Da, and has good biocompatibility and metabolic potential. The small molecule is self-assembled into nanoparticles with a particle size of about 130 nm, and has good colloidal stability and passive targeting ability. Meanwhile, the high molar absorption coefficient and high-efficiency photothermal conversion characteristics of the small molecule endow the small molecule with strong photoacoustic imaging capability, and the small molecule can be used for real-time monitoring of drug distribution and realization of 'diagnosis and treatment integration'.

This invention discloses a predictive model for assessing the risk of severe cytokine release syndrome (SCR) in patients with hematologic malignancies after CAR-T cell therapy. The model includes a nomogram and a prognostic risk scoring formula to assess the risk of SCR after CAR-T cell infusion. The biomarkers are the peripheral blood cytokine concentrations during 24-48 hours after CAR-T cell infusion, including five cytokines: CX3CL1, GZMB, IL4, IL6, and PDGFAA. The nomogram in this invention is the first predictive model established applicable to assessing the risk of SCR in patients with leukemia, lymphoma, and multiple myeloma undergoing CAR-T cell therapy. The model is simple, intuitive, and easy to implement, effectively helping clinicians assess the risk of SCR after CAR-T cell therapy, thus providing theoretical guidance for patient monitoring and treatment.

The application discloses YY20394 and ABT199 combination in the application of preparing a drug for treating acute myeloid leukemia. The application firstly finds that YY20394 and ABT199 have a synergistic effect on the treatment of acute myeloid leukemia, and the treatment effect of acute myeloid leukemia with MCL-1 overexpression can be significantly improved by combining YY20394 and ABT199. The application provides a brand-new treatment scheme for the technical field of blood system malignant tumor treatment, and has important scientific significance and clinical application value.